Patient Background
Harish Singhania, Male, 58 years. Regular patient since 2019. Last reviewed 12 March 2025 (3 days before this summary was prepared).
Active Diagnoses
| Condition | Stage / Status | Medication |
|---|
| Hypertension (Stage 2) | Controlled | Amlodipine 10 mg daily |
| Type 2 Diabetes (mild) | Controlled — dietary management | Metformin 500 mg twice daily |
| Mild Cognitive Impairment (MCI) | Early stage — newly diagnosed November 2024 | Donepezil 5 mg (trial basis) |
Note on Mild Cognitive Impairment
Mr. Singhania was diagnosed with early-stage MCI in November 2024 following a private neurological evaluation. At current stage, this does not significantly impair daily function. However, the patient expressed concern about disclosure to family members. He specifically requested this diagnosis not be shared with his wife or children, citing concerns about business control and inheritance matters. His legal counsel (K.K. Menon, Jaipur) was informed for estate planning purposes. MCI progression in the next 12–24 months is probable, per Dr. Mehta's neurological assessment.
Reason for Medical Summary
Prepared at patient's request for personal legal purposes (estate and divorce proceedings). The patient indicated he was restructuring significant financial arrangements and required a current medical opinion. He was advised to inform immediate family, which he declined.
Doctor's Observations — 12 March 2025 Visit
Patient appeared stressed but physically stable. He mentioned "significant family matters" were concluding in the coming weeks. He renewed his medication prescriptions for 90 days and asked about the interaction of his medications with alcohol. He was advised to limit alcohol intake to 1–2 units per occasion. He did not indicate any fear for his personal safety.